TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Chronic Obstructive Pulmonary Disease (COPD) Dual Therapy Burden of Illness

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* \>=2 International Statistical Classification of Diseases and Related Health Problems (ICD)-10-CM diagnosis codes for COPD at least 30 days apart during the 12 month period prior to sample identification.~* Diagnosis codes J40-J44 will be included.~* \>=1 pharmacy claim for UMEC/VI or FLUT/SAL single-inhaler dual therapy during Baseline.~* Age \>= 65 years.~* Self-reported health care provider diagnosis of COPD.~* Self-reported prescription for FLUT/SAL or UMEC/VI.~* 12 months of continuous enrollment during the Baseline period.~* Ability to complete the study survey in English.~Exclusion Criteria:~* \>=2 ICD-10-CM diagnosis codes for asthma at least 30 days apart during the, 12 month period, prior to sample identification.~* Claims for both UMEC/VI and FLUT/SAL in the 6 months, closest to sample identification.~* Claims for triple therapy (Inhaled Corticosteroid \[ICS\] + Long-acting Antimuscarinic \[LAMA\] + Long-acting Beta-agonist \[LABA\] during the Baseline period.~* Evidence of lung cancer diagnosis and/or treatment

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- UMEC/VI (Type: None): The subjects in this arm had received, UMEC/VI as 62.5/25 microgram (mcg), which is an approved once-daily single inhaler dual LAMA/LABA therapy, given via Ellipta .
- FLUT/SAL (Type: None): The subjects in this arm had received, FLUT/SAL as 250/50 mcg, which is an approved twice-daily single inhaler dual therapy ICS/LABA treatment, given via DISKUS.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Development of a mHealth Intervention for Ambivalent Smokers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DEVICE_FEASIBILITY
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years or older;~* Can speak/read English;~* Current smoker;~* Own and regularly use an eligible smartphone;~* No vision impairments;~* Willing to install and use the study program;~* Willing to use birth control if elect to use nicotine replacement during the study (females);~* Meet definition for ambivalence~* Not actively using treatment~Exclusion Criteria:~* Smoke less than 10 cigarettes per day~* Self-report a lifetime history of dementia, manic depression, bipolar disorder, or schizophrenia;~* Have medical contraindications for nicotine replacement therapy;~* Another household member is enrolled in the study~* Unable to verify contact information~* Fail to install app

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Control (Type: ACTIVE_COMPARATOR): None
- Experimental (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of MS as defined by McDonald et al, criteria, # 1- 4~* Between the ages of 18 and 55, inclusive~* Baseline EDSS score between 0.0 and 5.0, inclusive~* Have been treated with Avonex for at least the 12 months prior to randomization~* Have experienced at least one relapse (while on Avonex) within the 12 months prior to randomization.~* Cranial MRI scan demonstrating lesions consistent with MS.~* Have given written informed consent to participate in the study.~Exclusion Criteria:~* Primary progressive, secondary progressive, or progressive relapsing MS.~* MS relapse has occurred within 50 days of randomization~* A clinically significant infectious illness within 30 days prior to randomization~* History of, or abnormal lab result, indicative of significant disease, that in the opinion of the investigator, would preclude the administration of a recombinant humanized antibody immunomodulating agent or Avonex for 116 weeks.~* History of severe allergic or anaphylactic reactions or known drug hypersensitivity.~* Unable to perform the Timed 25-Foot Walk, 9HPT and PASAT 3~* Abnormal blood tests at Screening Visit

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: EXPERIMENTAL): Adding natalizumab monthly infusion to Avonex weekly injection for up to 116 weeks.
- Group 2 (Type: PLACEBO_COMPARATOR): Adding placebo monthly infusion to Avonex weekly injection for up to 116 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Direct and Indirect Protection by Influenza Vaccine Given to Children in India

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Inclusion in either vaccine group (TIV or IPV) will require ages 6 months through 10 years of age.~* All individuals in enrolled households will be eligible for enrollment into surveillance arm.~Exclusion Criteria:~* Exclusion criteria from the vaccine groups includes known allergy to eggs, or hypersensitivity to other components of a vaccine (streptomycin, neomycin, and polymyxin B)

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Inactivated Polio Vaccine (IPV) (Type: ACTIVE_COMPARATOR): Inactivated trivalent poliovirus vaccine (IPV) age Dose # doses/year 1 # doses year 2 and 3 6 mo -8y 0.5 ml 2 1 9-10 y 0.5 ml 1 1
- Inactivated Trivalent Influenza Vaccine (Type: EXPERIMENTAL): Inactivated split virion trivalent influenza vaccine (TIV) age Dose # doses year 1 # doses year 2 and 3 6-35 mo 0.25 ml 2 1 3-8 y 0.5 ml 2 1 9-10 y 0.5 ml 1 1
- Surveillance arm (Type: NO_INTERVENTION): Those ineligible for vaccination will be enrolled for febrile acute respiratory illness (FARI) surveillance to assess indirect effects of vaccination in household members.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Safety, Tolerability and Efficacy of NVA237 Versus Placebo

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of COPD (moderate-to-severe as classified by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines, 2008) and:~* Smoking history of at least 10 pack-years~* Post-bronchodilator FEV1 \< 80% and ≥ 30% of the predicted normal value~* Post-bronchodilator FEV1/FVC (forced vital capacity) \< 70%~Exclusion Criteria:~1. Patients who have had a lower respiratory tract infection within 6 weeks prior to Visit 1~2. Patients with concomitant pulmonary disease~3. Patients with a history of asthma~4. Any patient with lung cancer or a history of lung cancer~5. Patients with a history of certain cardiovascular comorbid conditions~6. Patients with a known history and diagnosis of alpha-1 antitrypsin deficiency~7. Patients in the active phase of a supervised pulmonary rehabilitation program~8. Patients contraindicated for tiotropium or ipratropium treatment or who have shown an untoward reaction to inhaled anticholinergic agents Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Glycopyrronium bromide (Type: EXPERIMENTAL): Glycopyrronium bromide 50µg delivered once daily via Single Dose Dry Powder Inhaler (SDDPI). At visit 1 all patients were provided with a short acting β2-agonist (salbutamol/albuterol) which they were instructed to use throughout the study as rescue medication.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo delivered once daily via SDDPI. At Visit 1 all patients were provided with a short acting β2-agonist (salbutamol/albuterol) which they were instructed to use throughout the study as rescue medication.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Growth Hormone Releasing Hormone in HIV

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Men and women age 18-65~2. Previously diagnosed HIV infection~3. Stable antiviral regimen for at least 12 weeks prior to enrollment~4. WC\>95 cm and WHR\>0.94 for male, WC\>94 cm and WHR\>0.88 for female occurring in the context of treatment for HIV disease~5. Subjective evidence of at least one of the following recent changes, occurring during the treatment of HIV disease: increased abdominal girth, relative loss of fat in the extremities, or relative loss of fat in the face~6. For female subjects 40yo or older, negative mammogram within one year of baseline~Exclusion Criteria:~1. Use of anti-diabetic agents, Megace, testosterone or any steroid use within 6 months of the study. Stable use of testosterone (\> 6 mos) at dose equivalent to 200 mg IM q 2 weeks or \< 10g/day to skin will be permitted.~2. Use of GH or GHRH within the past 6 months~3. Change in lipid lowering or antihypertensive regimen within 3 months of screening~4. Fasting blood sugar \> 126 mg/dL, SGOT \> 2.5 times ULN, HgB \< 12.0 g/dL, creatinine \> 1.4 mg/dL, CD4 count \< 200~5. Severe chronic illness or active malignancy or history of pituitary malignancy or history of colon cancer~6. For men, history of prostate cancer or evidence of prostate malignancy by PSA \> 5 ng/mL~7. Prior history of hypopituitarism, head irradiation or any other condition known to affect the GH axis~8. For women, positive urine hCG~9. Oral contraceptives, depo provera or combined progesterone-estrogen injections, transdermal contraceptive patches, estrogen or progestin coated IUD's within 6 months of the study.~10. Routine MRI exclusion criteria such as the presence of a pacemaker or cerebral aneurysm clip.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Tesamorelin (Type: EXPERIMENTAL): Tesamorelin (growth hormone releasing hormone) 2mg daily given subcutaneously x 6 months during randomized phase, followed by 6 months of open-label tesamorelin at same dose
- Placebo (inactive injection) (Type: PLACEBO_COMPARATOR): Placebo 2mg daily given subcutaneously for the first 6 months of the study, followed by 6 months of tesamorelin (growth hormone releasing hormone) 2mg daily during an open label phase

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Perioperative Intravenous Lidocaine Infusion on Postoperative Recovery in Patients Undergoing Arthroscopic Rotator Cuff Repair Under General Anesthesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. ASA class 1-3 adults over 19 years scheduled for elective arthroscopic rotator cuff repair~Exclusion Criteria:~1. Known allergies to lidocaine or propofol~2. Cardia arrhythmia~3. History of epilepsy or seizures~4. Liver/kidney failure~5. History of recent strong opioid use

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IV lidocaine (Type: EXPERIMENTAL): Perioperative IV lidocaine infusion
- Normal saline (Type: PLACEBO_COMPARATOR): Perioperative IV normal saline infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study for the Symptomatic Treatment of Chronic Idiopathic Urticaria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 18 to 70 years old.~* Documented history of CIU for at least 6 weeks prior to entry in the study.~Exclusion Criteria:~* Dermatological pathology other than chronic idiopathic urticaria.~* History of autoimmune disorders, Hodgkin's disease, lymphoma, leukemia and generalized cancer.~* Pregnant or breast-feeding women.~* Patients who will be operating heavy machinery or need to drive motor vehicles as an essential part of their profession.~* Patients who have a recent history (within previous 12 months) of drug addiction or alcohol abuse.~* Patients who are currently participating in or have participated in another clinical trial within the last 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Bilastine 20 mg
- 2 (Type: ACTIVE_COMPARATOR): Levocetirizine 5 mg
- 3 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Pegasys Versus Peg-Intron for Treatment of Chronic Hepatitis C Genotype 4

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult men and women~2. Age: 25 to 55 years with documented chronic hepatitis~3. Elevated serum alanine aminotransferase at least 2 times the upper limit of normal (40 U/L) on 2 occasions during the preceding 6 months~4. Detectable anti-HCV antibody status assessed by second-generation enzyme-linked immunosorbent assay (Roche Diagnostics, Branchburg, New Jersey); 5. Detectable HCV RNA by polymerase chain reaction (Cobas Amplicor HCV Monitor v2.0 \[Roche Diagnostics, Branchburg, New Jersey\]; lower limit of quantitation \[50 IU/mL\])~5. Infection with HCV genotype 4~6. Histologic evidence of chronic hepatitis C in a liver biopsy specimen obtained within the preceding year.~Exclusion Criteria:~1. Hepatitis A, hepatitis B, autoimmune hepatitis, alcoholic liver disease, drug-induced hepatitis.~2. Decompensated liver disease with a history of variceal hemorrhage, ascites, or hepatic encephalopathy.~3. Patients coinfected with schistosomiasis or human immunodeficiency virus~4. leukocyte count lower than 3000 /mm3, neutropenia (\<1500 cells/mm3), a hemoglobin level lower than 12 g/dL for women and lower than 13 g/dL for men, thrombocytopenia (\<90,000 cells/mm3), creatinine concentration 1.5 times the upper limit of normal~5. Organ transplantation~6. Neoplastic disease~7. Severe cardiac or pulmonary disease~8. Unstable thyroid dysfunction~9. Psychiatric disorder~10. Current pregnancy or breast feeding.~11. Therapy with immunomodulatory agents within the last 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Pegylated interferon alpha 2a plus ribavirin
- 2 (Type: ACTIVE_COMPARATOR): Pegylated interferon alpha 2b plus ribavirin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A New Anthrax Vaccine Administered by the Intramuscular (IM) Route in Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Volunteers are eligible for this study if they meet all the following criteria:~* Citizens of the U.S.~* Age 18 to 40 years.~* For women, a negative serum pregnancy test will be required at study entry and within 24 hours prior to each vaccination, as well as verbal assurance that adequate birth control measures are applied prior to initial vaccination and for 3 months after the last vaccination.~* Good health as determined by medical history, physical examination, and clinical judgment.~* Normal Baseline Clinical Laboratory Values at screening including:~  * Complete Blood Count (CBC) including:~ * White Blood Cell Count: 3.8 -10.8~ * Red Blood Cell Count (Mill/MCL)~ * Male: 4.20 - 5.80~ * Female: 3.80 - 5.10~ * Hemoglobin (G/DL)~ * Male: 13.2 - 17.1~ * Female: 11.7 - 15.5~ * Hematocrit (%)~ * Male: 38.5- 50.0~ * Female: 35.0 - 45.0~ * Platelet Count: 140 - 440 (THOUS/MCL)~ * Differential~ * Urine dipstick for protein and blood: negative or trace. If either is ≥ 1+, obtain complete urinalysis (UA). If microscopic UA confirms evidence of hematuria or proteinuria ≥ 1+, the volunteer is ineligible.~ * Negative serology for HIV infection (ELISA test).~ * CPK within normal limits~ * Hepatic Function Tests including AST, ALT, ALK PHOS.~ * Total bilirubin, BUN, serum creatinine, serum electrolytes~* Availability for at least 13 months of follow-up from the time of the screening visit.~* Successful completion of the Test of Understanding defined as 90% correct with three opportunities to take test. Errors will be reviewed with volunteer after each test.~* Commitment for trial participation and signature of the approved consent form.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Anthrax vaccine with or without PBS (Type: EXPERIMENTAL): Administor 1 dose 5 μg rPA with PBS (5 Volunteers)
- Placebo (Type: PLACEBO_COMPARATOR): Doses will range from 5 _g to 100 _g rPA, and at each dose-level, rPA will either be combinedwith phosphate-buffered saline (PBS) or adsorbed to Alhydrogel

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* Informed consent.~* Outpatient.~* Females of child-bearing potential must use appropriate contraception.~* Diagnosis of seasonal allergic rhinitis to mountain cedar.~* Adequate exposure to allergen.~* Able to comply with study procedures.~* Literate.~Exclusion criteria:~* Significant concomitant medical condition.~* Use of corticosteroids, allergy medications, or other medication that affect allergic rhinitis~* Positive pregnancy test.~* Allergy to any component of the investigational product.~* Tobacco use~* Contact lens use~* Has chickenpox or measles or recent exposure~* Other clinical trial drug exposure in last 30 days~* Affiliation with clinic site

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 18 years old.~* Medical record documentation of recurrent CDI including a positive C. difficile test within 60 days prior to enrollment and either: a) at least two recurrences after a primary episode and has completed at least two rounds of standard-of-care oral antibiotic therapy or b) has had at least two episodes of severe CDI resulting in hospitalization.~* Documented history that the subject's recurrent CDI is controlled while on antibiotics even if the subject is not currently on antibiotics.~* A positive stool test for the presence of C. difficile within 60 days prior to enrollment~Exclusion Criteria:~* A known history of continued CDI diarrhea despite being on a course of antibiotics prescribed for CDI treatment.~* Requires continuous antibiotic therapy for a condition other than CDI.~* Previous successful (resolution of CDI diarrhea) fecal transplant for recurrent CDI \< 6 months prior to study enrollment.~* Previous unsuccessful (recurrent CDI diarrhea was unresolved) fecal transplant.~* Previous treatment with RBX2660.~* Diagnosis of inflammatory bowel disease (IBD), e.g., ulcerative colitis, Crohn's disease, or microscopic colitis.~* Diagnosis of irritable bowel syndrome (IBS) as determined by Rome III criteria.~* History of chronic diarrhea.~* History of celiac disease.~* Disease symptoms caused by a confirmed intestinal pathogen other than C. difficile.~* Colostomy.~* Planned surgery requiring perioperative antibiotics within 3 months of study enrollment.~* Life expectancy of \< 12 months.~* Compromised immune system

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RBX2660 Open-label (Type: EXPERIMENTAL): RBX2660 (microbiota suspension)
- Historical control antibiotics (Type: OTHER): Retrospective Historical Control with standard of care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete